CreoSG Secures Canadian Patent for MERS Vaccine

On June 26, CreoSG announced that it has obtained a Canadian patent for its recombinant VSV vector-based MERS vaccine, which was registered through its subsidiary, Smagen Canada.

The recombinant VSV platform technology (brand name: SUV-MAP) is a core technology for developing various vaccines. It enables the creation of recombinant viruses carrying target antigen genes, which can then be mass-produced in cultured cells and used as vaccine raw materials. CreoSG is currently developing AIDS vaccines, COVID-19 vaccines, and hantavirus vaccines using SUV-MAP, through its own vaccine research institute and Smagen Canada.

The VSV-MERS vaccine is a product that maximizes vaccine efficacy by loading the MERS-CoV viral envelope protein onto the SUV-MAP vaccine platform, which is based on a recombinant VSV vector created through genetic recombination methods. This vaccine was also patented in Saudi Arabia in March 2026.

Middle East Respiratory Syndrome (MERS) is a viral respiratory disease caused by the Middle East Respiratory Syndrome coronavirus (MERS-CoV), first identified in Saudi Arabia in 2012. The disease primarily attacks the respiratory system and can cause a range of symptoms from mild to severe. In particular, it can become fatal if it progresses to pneumonia. As there are currently no approved vaccines or specific antiviral treatments, the need for a vaccine is even more pronounced.

A representative from CreoSG stated, "With the acquisition of a Canadian patent following Saudi Arabia, our technological capabilities have once again been recognized," adding, "We are now planning a vaccine development roadmap that will enable us to commercialize the MERS vaccine."

This content was produced with the assistance of AI translation services.